CoChat
Sign Up
Cited by 502Sepsis Diagnosis and TreatmentAntibiotics Pharmacokinetics and EfficacyAcute Kidney Injury Research

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

Open access
Dellinger, R. Phillip, Bagshaw, Sean M., Antonelli, Massimo, Foster, Debra M., Klein, David J., Marshall, John C., Palevsky, Paul M., Weisberg, Lawrence S., Schorr, Christa A., Trzeciak, Stephen, Walker, Paul M., for the EUPHRATES Trial Investigators·2018·JAMA
DOI 10.1001/jama.2018.14618PMC PMC6233793
Open this paper in CoChat — free accountOpen PDF

Abstract

Importance: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes. Objective: To test whether adding polymyxin B hemoperfusion to conventional medical therapy improves survival compared with conventional therapy alone among patients with septic shock and high endotoxin activity. Design, Setting, and Participants: Multicenter, randomized clinical trial involving 450 adult critically ill patients with septic shock and an endotoxin activity assay level of 0.60 or higher enrolled between September 2010 and June 2016 at 55 tertiary hospitals in North America. Last follow-up was June 2017. Interventions: Two polymyxin B hemoperfusion treatments (90-120 minutes) plus standard therapy completed within 24 hours of enrollment (n = 224 patients) or sham hemoperfusion plus standard therapy (n = 226 patients). Main Outcomes and Measures: The primary outcome was mortality at 28 days among all patients randomized (all participants) and among patients randomized with a multiple organ dysfunction score (MODS) of more than 9. Results: Among 450 eligible enrolled patients (mean age, 59.8 years; 177 [39.3%] women; mean APACHE II score 29.4 [range, 0-71 with higher scores indicating greater severity), 449 (99.8%) completed the study. Polymyxin B hemoperfusion was not associated with a significant difference in mortality at 28 days among all participants (treatment group, 84 of 223 [37.7%] vs sham group 78 of 226 [34.5%]; risk difference [RD], 3.2%; 95% CI, -5.7% to 12.0%; relative risk [RR], 1.09; 95% CI, 0.85-1.39; P = .49) or in the population with a MODS of more than 9 (treatment group, 65 of 146 [44.5%] vs sham, 65 of 148 [43.9%]; RD, 0.6%; 95% CI, -10.8% to 11.9%; RR, 1.01; 95% CI, 0.78-1.31; P = .92). Overall, 264 serious adverse events were reported (65.1% treatment group vs 57.3% sham group). The most frequent serious adverse events were worsening of sepsis (10.8% treatment group vs 9.1% sham group) and worsening of septic shock (6.6% treatment group vs 7.7% sham group). Conclusions and Relevance: Among patients with septic shock and high endotoxin activity, polymyxin B hemoperfusion treatment plus conventional medical therapy compared with sham treatment plus conventional medical therapy did not reduce mortality at 28 days. Trial Registration: ClinicalTrials.gov Identifier: NCT01046669.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2018.14618

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

Sorted by citations

Items 301–400 of 501

Related

See all

Metadata

Authors
Dellinger, R. P., Bagshaw, S. M., Antonelli, M., Foster, D. M., Klein, D. J., Marshall, J. C., Palevsky, P. M., Weisberg, L. S., Schorr, C. A., Trzeciak, S., Walker, P. M., & for the EUPHRATES Trial Investigators
Affiliations
  • Cooper University Hospital (US)
  • University of Alberta (CA)
  • Università Cattolica del Sacro Cuore (IT)
  • Spectral Medical Inc, Toronto, Canada
  • St. Michael's Hospital (CA)
  • University of Pittsburgh (US)
Corresponding author
Dellinger, R. Phillip
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2018-10-09
Volume
320
Issue
14
Pages
1455
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.2018.14618
PMC
PMC6233793
OpenAlex
W2897735762
Cited by
502
References
25
Citations by year
2026: 73 · 2025: 71 · 2024: 71 · 2023: 70 · 2022: 52 · 2021: 54 · 2020: 63 · 2019: 40 · 2018: 5
FWCI
31.62
Type
journal article
Language
en
Open access
Locations
  • JAMA (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion)
  • Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
Funders
  • University of Nebraska Medical Center
  • Memorial Sloan-Kettering Cancer Center
  • Cleveland Clinic
  • University of Pittsburgh
  • East Carolina University
  • Thomas Jefferson University
  • Temple University
  • University of Alberta
  • Medical Center, University of Pittsburgh
Topics
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
polymyxin B hemoperfusion, septic shock, endotoxin activity, endotoxemia, 28-day mortality, multiple organ failure, sepsis, critically ill patients, endotoxin activity assay, survival outcomes, sepsis treatment, APACHE II score, multiple organ dysfunction score, sepsis mortality
MeSH terms
Adult, Aged, Anti-Bacterial Agents, Endotoxins, Female, Humans, Male, Middle Aged, Polymyxin B, Shock, Septic, Survival Analysis, Hospital Mortality, APACHE

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review